Prescribing in COVID-19 patients: Should we take into account inflammation?

Marzolini, Catia; Battegay, Manuel; Sendi, Parham; Back, David J

Marzolini, Catia; Battegay, Manuel; Sendi, Parham; Back, David J.

Marzolini C; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel and University of Basel, Basel, Switzerland.
Battegay M; Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Sendi P; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel and University of Basel, Basel, Switzerland.
Back DJ; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel and University of Basel, Basel, Switzerland.

Br J Clin Pharmacol ; 87(3): 719-721, 2021 03.

Article in English | MEDLINE | ID: covidwho-725047

Subject(s)

Anti-Inflammatory Agents/therapeutic use; COVID-19 Drug Treatment; COVID-19/complications; Drug Prescriptions; Inflammation/drug therapy; Inflammation/etiology; Antiviral Agents/therapeutic use; Drug Therapy, Combination; Humans

Keywords

COVID-19; drug-drug interactions; inflammation; inhibition drug metabolism

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Drug Prescriptions / COVID-19 / COVID-19 Drug Treatment / Inflammation / Anti-Inflammatory Agents Topics: Long Covid Limits: Humans Language: English Journal: Br J Clin Pharmacol Year: 2021 Document Type: Article Affiliation country: Bcp.14524

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google